Clinical trials: Papillomavirus Infections
Infections, Papillomavirus
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00120848
- Testing
- HPV 16/18 VLP AS04
- Where
- 27 sites in United States, Brazil and 1 more
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Infection, Self Sampling
HPV Typing Between Self- and Physician-sampled
Hygeia Touch Inc. developed a safe and comfortable vaginal self-sampling device "Hygeia Touch Self Sampling Kit for Women" to self-collect the vaginal discharge sample for high-risk Human Papillomavirus (hrHPV) detection.
- Conditions
- Human Papillomavirus Infection, Self Sampling, Vaginal Discharge
- Trial name
- NCT04472377
- Testing
- Self sampling kit for collecting discharge from vaginal fornix
- Where
- 3 sites in Taiwan
- Volunteers
- 1,210 people, healthy volunteers welcome
- Sponsor
- Hygeia Touch Inc.
Human Papillomavirus Infection
An Observational Study on the Prevalence of Human Papillomavirus Types in Women in the Kingdom of Bahrain
The purpose of this study is to determine the Human Papillomavirus (HPV) prevalence and HPV type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for…
- Trial name
- NCT01205412
- Testing
- Endocervical samples
- Where
- Bahrain
- Volunteers
- 552 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Wart
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients
This phase II study is to evaluate the efficacy of SR-T100 gel in complete clearance of target warts at different concentrations (1.0% and 2.3% of SM in Solanum undatum plant extract) in patients with CW.
- Trial name
- NCT01796795
- Testing
- Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM
- Volunteers
- 102 people
- Sponsor
- G&E Herbal Biotechnology Co., LTD
Infections, Papillomavirus
Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
Human papillomavirus infection has clearly been recognized as the cause of cervical cancer. The infection of the cervix by certain oncogenic types of HPV, if not cleared, can lead to cervical cancer in women.
- Trial name
- NCT00345878
- Testing
- HPV-16/18 L1 VLP AS04 (Cervarix TM)
- Where
- 2 sites in Malaysia
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Solid Tumors, Mycosis Fungoides
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides.
- Conditions
- Solid Tumors, Mycosis Fungoides, Melanoma, Merkel-cell Carcinoma
- Trial name
- NCT02890368
- Testing
- TTI-621 Monotherapy, TTI-621 + PD-1/PD-L1 Inhibitor, TTI-621 + pegylated interferon-α2a
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Pfizer
Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis
Zopapogene Imadenovec for the Treatment of Recurrent Respiratory Papillomatosis in Children
Recurrent respiratory papillomatosis (RRP) is a rare disease in which wart-like growths caused by human papillomavirus (HPV) types 6 or 11 form in the airway.
- Conditions
- Recurrent Respiratory Papillomatosis (RRP), Juvenile-onset Recurrent Respiratory Papillomatosis, Papillomavirus Infections
- Trial name
- NCT07901738
- Testing
- Zopapogene imadenovec-drba
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Precigen, Inc
CIN 2/3, HPV Infection
Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).
- Conditions
- CIN 2/3, HPV Infection, Pre-Cancerous Dysplasia, Cervical Dysplasia
- Trial name
- ART-CIN_IIB (NCT04098744)
- Testing
- Artesunate vaginal insert
- Where
- 7 sites in United States
- Volunteers
- 78 people
- Sponsor
- Frantz Viral Therapeutics, LLC
Genital Warts
Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts
The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.
- Trial name
- NCT00499967
- Testing
- GS-9191 ointment, GS-9191
- Where
- 25 sites in United States
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
Infections, Papillomavirus
Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infection with human papillomavirus (HPV) has been clearly established as the central cause of cervical cancer. Vaccination of pre-teens and adolescents, ideally before sexual debut and thus before exposure to oncogenic HPV, is a…
- Trial name
- NCT00578227
- Testing
- Cervarix™, Twinrix ™ Paediatric
- Where
- 21 sites in Canada, Denmark and 2 more
- Volunteers
- 814 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Common Wart
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
- Trial name
- NCT03278028
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 16 sites in United States
- Volunteers
- 159 people
- Sponsor
- Aclaris Therapeutics, Inc.
HPV Infection
Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV
Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1.
- Trial name
- 9vHPV-BCG (NCT06959563)
- Testing
- 9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Anogenital Warts
Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts
An exploratory open label, single treatment trial of anogenital warts with Picato® repeated up to 2 times with two weeks intervals.
- Trial name
- NCT02377999
- Testing
- Picato
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- LEO Pharma
Genital Warts
Study of Imiquimod Cream Prior to Ablative Therapy in External Ano-Genital Warts
The purpose of this study is to compare the recurrence rate following total clearance of external genital warts (EGWs) when clearance has been obtained by imiquimod (3 applications per week for 4 weeks) followed by ablative…
- Trial name
- NCT00189293
- Testing
- Imiquimod, vehicle cream
- Where
- 12 sites in Italy
- Volunteers
- 128 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Cervical Intraepithelial Neoplasia, Papillomavirus Infection
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine
This protocol posting deals with objectives \& outcome measures of the extension phase up to Month 48. The objective of the extension study is to evaluate the long-term immunogenicity of the HPV 16/18 L1 VLP AS04 vaccine (for all…
- Trial name
- NCT00316706
- Testing
- GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™
- Where
- 28 sites in Colombia, Germany and 3 more
- Volunteers
- 1,245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infection by Human Papilloma Virus
Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)
To support international market access and comply with World Health Organization Prequalification requirements, this lot-to-lot consistency trial is planned for initiation.
- Trial name
- NCT07668271
- Testing
- 9-valent HPV vaccine (Cecolin 9)
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Human Papillomavirus Infection
Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine
This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).
- Trial name
- NCT01702337
- Testing
- Prevalence-based model
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus Infection
Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)
This is a post-licensure safety observation cohort study to describe the general safety of GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.
- Trial name
- NCT01567813
- Volunteers
- 114,035 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections
Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)
This study will evaluate the efficacy, immunogenicity and safety of 9-valent human papillomavirus (9vHPV; V503) vaccine in Chinese women 20 to 45 years of age.
- Trial name
- NCT03998254
- Testing
- V503, Gardasil
- Where
- 6 sites in China
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC